Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  New Zealand Stock Exchange  >  AFT Pharmaceuticals Limited    AFT   NZAFTE0001S4

AFT PHARMACEUTICALS LIMITED

(AFT)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AFT Pharmaceuticals : AFP determination of Anita Baldauf independenceOpens in a new Window

12/14/2020 | 08:53pm EDT

Market and media release

15th December 2020

AFT determination of Anita Baldauf independence

As announced on 4 November 2020, AFT Pharmaceuticals (NZX; AFT, ASX; AFP) appointed Anita Baldauf as a non-executive director. In accordance with NZX Listing Rule 2.6.1, the Board has determined that she is an Independent Director (within the meaning of the NZX Listing Rules).

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.

For more information:

Investors

Media

Malcolm Tubby

Richard Inder

CFO

The Project

AFT Pharmaceuticals

Tel: +64 21 645 643

Tel: +64 9488 0232

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand

Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

AFT Pharmaceuticals Limited published this content on 15 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 December 2020 01:52:03 UTC


© Publicnow 2020
All news about AFT PHARMACEUTICALS LIMITED
04/13SHINTR : AFT: D&O Ongoing Disclosure - Louise ClaytonOpens in a new Window
PU
04/13SHINTR : AFT: D&O Ongoing Disclosure - Malcolm TubbOpens in a new Window
PU
04/13SECISSUE : AFT: Capital Change Notice - Issue of ordinary sharesOpens in a new W..
PU
04/12AFT Pharma's Hand Sanitizer Set for Distribution in Middle East, Africa
MT
04/11AFT PHARMACEUTICALS  : Crystawash Extend distribution in UAE, Kuwait, Oman and K..
PU
04/06AFT PHARMACEUTICALS  : Partners With Poland's Mercapharm and Greece's Vianex for..
MT
04/06GENERAL : AFT: AFT secures new partners in Poland and Greece Opens in a new Wind..
PU
04/01AFT PHARMACEUTICALS  : Lowers Fiscal 2021 Operating Profit Guidance
MT
04/01AFT PHARMACEUTICALS  : Lowers Earnings Guidance for Fiscal 2021 Due to Licensing..
MT
03/31GENERAL : AFT: AFT updates earnings guidanceOpens in a new Window
PU
More news
Financials
Sales 2021 110 M 78,8 M 78,8 M
Net income 2021 7,79 M 5,57 M 5,57 M
Net Debt 2021 31,8 M 22,7 M 22,7 M
P/E ratio 2021 57,0x
Yield 2021 -
Capitalization 444 M 317 M 317 M
EV / Sales 2021 4,31x
EV / Sales 2022 3,58x
Nbr of Employees 86
Free-Float 28,2%
Chart AFT PHARMACEUTICALS LIMITED
Duration : Period :
AFT Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AFT PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 4,61 NZD
Last Close Price 4,24 NZD
Spread / Highest target 15,6%
Spread / Average Target 8,61%
Spread / Lowest Target 1,65%
EPS Revisions
Managers and Directors
NameTitle
Hartley Atkinson Chief Executive Officer, MD & Executive Director
Malcolm Tubby Chief Financial Officer & Secretary
David Mark Flacks Chairman
Douglas John Wilson Independent Non-Executive Director
Jon Lamb Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AFT PHARMACEUTICALS LIMITED-23.05%316
JOHNSON & JOHNSON1.33%419 864
ROCHE HOLDING AG-0.95%285 584
PFIZER INC.0.43%207 285
NOVARTIS AG-4.61%195 170
MERCK & CO., INC.-6.56%193 467